Cash Flow Statement

Altimmune (ALT) Amortizatization of Intangibles (2016 - 2026)

Altimmune (ALT) reported Amortizatization of Intangibles of $870000.0 for Q1 2026, up 26.82% year-over-year from $686000.0 in Q1 2025, and down 4.5% on a QoQ basis from $911000.0 in Q4 2025.

Altimmune (ALT) has 9 years of Amortizatization of Intangibles data on file, last reported at $870000.0 in Q1 2026.

  • Quarterly Amortizatization of Intangibles rose 26.82% year-over-year to $870000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 32.23% YoY) and the FY2025 annual result came in at $2.2 million, down 42.23% from the prior year.
  • Amortizatization of Intangibles retreated to $870000.0 in Q1 2026 per ALT's latest filing, from $911000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q2 2024 and bottomed at $196000.0 in Q3 2025.
  • The 4-year median for Amortizatization of Intangibles is $695000.0 (2023), against an average of $724230.8.
  • The widest annual swing landed in 2024, when Amortizatization of Intangibles surged 104.37%; it then slumped 79.98% in 2025.
  • Tracing ALT's Amortizatization of Intangibles over 4 years: stood at $695000.0 in 2023, then rose by 17.84% to $819000.0 in 2024, then gained by 11.23% to $911000.0 in 2025, then slipped by 4.5% to $870000.0 in 2026.
  • Per Business Quant, the three latest ALT Amortizatization of Intangibles figures stand at $870000.0 (Q1 2026), $911000.0 (Q4 2025), and $196000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 13,267.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Altimmune 379.61 Mn 379.61 Mn - 870,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 870,000.00
Mar 31, 2026 870,000.00
Dec 31, 2025 911,000.00
Dec 31, 2025 911,000.00
Sep 30, 2025 196,000.00
Sep 30, 2025 196,000.00
Jun 30, 2025 431,000.00
Jun 30, 2025 431,000.00
Mar 31, 2025 686,000.00
Mar 31, 2025 686,000.00
Dec 31, 2024 819,000.00
Dec 31, 2024 819,000.00
Sep 30, 2024 979,000.00
Sep 30, 2024 979,000.00
Jun 30, 2024 1.07 Mn
Jun 30, 2024 1.07 Mn
Mar 31, 2024 983,000.00
Mar 31, 2024 983,000.00
Dec 31, 2023 695,000.00
Dec 31, 2023 695,000.00
Sep 30, 2023 669,000.00
Sep 30, 2023 669,000.00
Jun 30, 2023 626,000.00
Jun 30, 2023 626,000.00
Mar 31, 2023 481,000.00
Mar 31, 2023 481,000.00
Sep 30, 2020 10,406.00
Sep 30, 2020 10,406.00
Jun 30, 2020 12,025.00
Jun 30, 2020 12,025.00
Mar 31, 2020 13,851.00
Mar 31, 2020 13,851.00
Dec 31, 2019 11,836.00
Dec 31, 2019 11,836.00
Sep 30, 2019 28,084.00
Sep 30, 2019 28,084.00
Jun 30, 2019 14,836.00
Jun 30, 2019 14,836.00
Mar 31, 2019 92,744.00
Mar 31, 2019 92,744.00
Dec 31, 2018 38,226.00
Dec 31, 2018 38,226.00
Sep 30, 2018 15,980.00
Sep 30, 2018 15,980.00
Jun 30, 2018 14,818.00
Jun 30, 2018 14,818.00
Mar 31, 2018 14,628.00
Mar 31, 2018 14,628.00
Dec 31, 2017 14,776.00
Dec 31, 2017 14,776.00
Sep 30, 2017 14,257.00
Sep 30, 2017 14,257.00
Jun 30, 2017 13,597.00
Jun 30, 2017 13,597.00
Mar 31, 2017 12,555.00
Mar 31, 2017 12,555.00
Dec 31, 2016 11,684.00
Dec 31, 2016 11,684.00
Sep 30, 2016 11,764.00
Sep 30, 2016 11,764.00